Pulmonary Embolism - Pipeline Insight, 2021
This report can be delivered to the clients within 24 hours
DelveInsight’s, “Pulmonary Embolism - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Pulmonary Embolism pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Pulmonary Embolism: Overview
Pulmonary embolism (PE) describes a blockage of one of the pulmonary arteries by a blood clot that forms elsewhere in the body and travels to the lung. The symptoms of pulmonary embolism may include pleuritic chest pain, shortness of breath, rapid heart rate, and anxiety. The diagnosis of PE is most often confirmed by lung CT scan or pulmonary angiography. Treatment of pulmonary embolism is aimed at keeping the blood clot from getting bigger and preventing new clots from forming. Prompt treatment is essential to prevent serious complications or death. Anticoagulant medications, such as heparin, enoxaparin, or warfarin are usually given to help thin the blood and prevent further clotting. The major complication of anticoagulation is bleeding.
'Pulmonary Embolism - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pulmonary Embolism pipeline landscape is provided which includes the disease overview and Pulmonary Embolism treatment guidelines. The assessment part of the report embraces, in depth Pulmonary Embolism commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pulmonary Embolism collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Pulmonary Embolism report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Pulmonary Embolism Emerging Drugs
Further product details are provided in the report……..
Pulmonary Embolism: Therapeutic Assessment
This segment of the report provides insights about the different Pulmonary Embolism drugs segregated based on following parameters that define the scope of the report, such as:
Pulmonary Embolism: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Pulmonary Embolism therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pulmonary Embolism drugs.
Pulmonary Embolism Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Pulmonary Embolism - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Pulmonary Embolism pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Pulmonary Embolism: Overview
Pulmonary embolism (PE) describes a blockage of one of the pulmonary arteries by a blood clot that forms elsewhere in the body and travels to the lung. The symptoms of pulmonary embolism may include pleuritic chest pain, shortness of breath, rapid heart rate, and anxiety. The diagnosis of PE is most often confirmed by lung CT scan or pulmonary angiography. Treatment of pulmonary embolism is aimed at keeping the blood clot from getting bigger and preventing new clots from forming. Prompt treatment is essential to prevent serious complications or death. Anticoagulant medications, such as heparin, enoxaparin, or warfarin are usually given to help thin the blood and prevent further clotting. The major complication of anticoagulation is bleeding.
'Pulmonary Embolism - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pulmonary Embolism pipeline landscape is provided which includes the disease overview and Pulmonary Embolism treatment guidelines. The assessment part of the report embraces, in depth Pulmonary Embolism commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pulmonary Embolism collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Pulmonary Embolism R&D. The therapies under development are focused on novel approaches to treat/improve Pulmonary Embolism.
This segment of the Pulmonary Embolism report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Pulmonary Embolism Emerging Drugs
- Recombinant staphylokinase: Supergene
- Recombinant human prourokinase: Tasly Pharmaceuticals
Further product details are provided in the report……..
Pulmonary Embolism: Therapeutic Assessment
This segment of the report provides insights about the different Pulmonary Embolism drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Pulmonary Embolism
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Pulmonary Embolism: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Pulmonary Embolism therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pulmonary Embolism drugs.
Pulmonary Embolism Report Insights
- Pulmonary Embolism Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Pulmonary Embolism drugs?
- How many Pulmonary Embolism drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pulmonary Embolism?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Pulmonary Embolism therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Pulmonary Embolism and their status?
- What are the key designations that have been granted to the emerging drugs?
- Supergene
- Servier
- Daiichi Sankyo Company
- Tasly Pharmaceuticals
- Yuhan
- Recombinant staphylokinase
- S-62798
- DS 1040
- Recombinant human prourokinase
- YHP1906
Introduction
Executive Summary
Pulmonary Embolism: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Pulmonary Embolism – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Recombinant staphylokinase: Supergene
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
Recombinant human prourokinase: Tasly Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
YHP1906: Yuhan
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Preclinical/Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Pulmonary Embolism Key Companies
Pulmonary Embolism Key Products
Pulmonary Embolism- Unmet Needs
Pulmonary Embolism- Market Drivers and Barriers
Pulmonary Embolism- Future Perspectives and Conclusion
Pulmonary Embolism Analyst Views
Appendix
Executive Summary
Pulmonary Embolism: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Pulmonary Embolism – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Recombinant staphylokinase: Supergene
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
Recombinant human prourokinase: Tasly Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
YHP1906: Yuhan
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Preclinical/Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Pulmonary Embolism Key Companies
Pulmonary Embolism Key Products
Pulmonary Embolism- Unmet Needs
Pulmonary Embolism- Market Drivers and Barriers
Pulmonary Embolism- Future Perspectives and Conclusion
Pulmonary Embolism Analyst Views
Appendix
LIST OF TABLES
Table 1 Total Products for Pulmonary Embolism
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Pulmonary Embolism
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Pulmonary Embolism
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Pulmonary Embolism
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
